Fundraising Fox
Alveogene
Founded 2022 · 4 employees on LinkedIn · 1 known investors
Find your way into Alveogene
Sign up to see every warm intro you have to Alveogene
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alveogene team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
Founders & leadership
DH
David HipkissExecutive ChairDavid Hipkiss is Executive Chair of AlveoGene, a respiratory gene therapy company. He has held senior leadership roles including Chair and CEO positions across pharmaceutical and biotech companies over three decades, with experience in corporate development, fundraising, and commercialization of biotech platforms.
Investors · 1
Oxford Science Enterpriseslisted by Oxford Science EnterprisesOxford · $63.5K – $31.8M
How we know: Oxford Science Enterprises's portfolio page · a partner's Signal profile · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- ALVEOGENE LIMITED
- Company number
- 14342459
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 7 Sept 2022
- Registered office
- C/O Oxford Science Enterprises, 46 Woodstock Road, Oxford, OX2 6HT
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 6 Sept 2025 · next due 20 Sept 2026
Current officers · 5
- Eric Walter Frederick Wolfgang Alton — director, appointed 7 Sept 2022
- Claire Brown — director, appointed 24 Jul 2023
- David John Hipkiss — director, appointed 24 Jul 2023
- Alistair James Mcdermott — director, appointed 11 Jul 2025
- John Rice — director, appointed 24 Jul 2023
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Alveogene do?
- AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.
- Who are Alveogene's investors?
- Alveogene's investors include Oxford Science Enterprises.